Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysis: Four Major Drugmakers Likely to Top FY07 Earnings Forecasts (Japan)

This article was originally published in PharmAsia News

Executive Summary

Earnings for Japan's top four pharmaceutical companies are already expected to exceed annual projections. This prediction is made based on surprisingly strong first quarter performances by Takeda Pharmaceutical Co., Astellas Pharma Inc., Daiichi Sankyo Co., and Eisai Co. In fact, Daiichi Sankyo has already achieved 43 percent of its forecasted pretax profit for the year, while Takeda, Astellas, and Eisai have made 33 percent, 29 percent, and 25 percent respectively. Healthy international sales, combined with a relatively weak yen, have been the major cause of the booming profit margins. Takeda's biggest overseas earner was Actos, a diabetes medication. Astellas got a boost from Prograf, which prevents organ rejection. And Eisai's success largely stemmed from Aricept, its anti-Alzheimer's drug. Even if the yen does get stronger, it is unlikely it will have much effect on the earnings of these companies. This factor leads experts to believe all four companies will probably raise their expected annual earnings after announcing figures for the first half of the year in October. (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel